ReviewCell death & disease2014
Systems biology approaches to develop innovative strategies for lung cancer therapy.
Review in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Global research and emerging trends in autophagy in lung cancer: a bibliometric and visualized study from 2013 to 2022.Frontiers in pharmacology · 2024Pooled it
- PRMT5, regulated by lncRNA ZFAS1/miR-150-5p, promoted androgen-independent prostate cancer migration and invasion.Archives of medical science : AMS · 2025Article
- Comprehensive analysis of multiple regulated cell death risk signatures in lung adenocarcinoma.Heliyon · 2024Article
- Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways.Diseases (Basel, Switzerland) · 2024Review
- Data-driven structural analysis of small cell lung cancer transcription factor network suggests potential subtype regulators and transition pathways.NPJ systems biology and applications · 2023Article
- Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis.Biomedicines · 2023Review
- Clinical Network Systems Biology: Traversing the Cancer Multiverse.Journal of clinical medicine · 2023Review
- Review
- Correlation of Tryptophan Metabolic Pathway with Immune Activation and Chemosensitivity in Patients with Lung Adenocarcinoma.Journal of oncology · 2022Article
- Article
- Novel Frog Skin-Derived Peptide Dermaseptin-PP for Lung Cancer Treatment:Frontiers in chemistry · 2020Article
- Cell death-based treatment of lung adenocarcinoma.Cell death & disease · 2018Review
- INO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer.Oncogene · 2017Article
- Sensitization strategies in lung cancer.Oncology letters · 2016Article
- Systems biology: a way to make complex problems more understandable.Cell death & disease · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) is a number one killer of cancer-related death among men and women worldwide. Major advances have been made in the diagnosis, staging and use of surgery for LC, but systemic chemotherapy and radiotherapy alone or in combination with some targeted agents remains the core treatment of advanced LC. Unfortunately, in spite of improved diagnosis, surgical methods and new treatments, mortality is still extremely high among LC patients. To understand the precise functioning of signaling pathways associated with resistance to current treatments in LC, as well as to identify novel treatment regimens, a holistic approach to analyze signaling networks should be applied. Here, we describe systems biology-based approaches to generate biomarkers and novel therapeutic targets in LC, as well as how this may contribute to personalized treatment for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.